Crinetics Pharmaceuticals Q2 EPS $(0.94) Misses $(0.86) Estimate, Sales $988.00K Beat $560.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 losses of $(0.94) per share, missing the analyst consensus estimate of $(0.86) by 9.3%. This is a 16.05% decrease from the same period last year. However, the company reported quarterly sales of $988.00K, beating the analyst consensus estimate of $560.00K by 76.43%, a 125.06% increase from last year.
August 08, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Crinetics Pharmaceuticals reported a larger than expected Q2 loss but beat sales estimates. This mixed report may lead to uncertain short-term price movements.
Crinetics Pharmaceuticals reported a larger loss than expected, which is negative for the stock. However, the company also reported higher sales than expected, which is positive. These mixed results make the short-term price impact uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100